309 related articles for article (PubMed ID: 24559582)
21. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
[TBL] [Abstract][Full Text] [Related]
22. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
[TBL] [Abstract][Full Text] [Related]
23. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
Yoon KH; Shockey GR; Teng R; Golm GT; Thakkar PR; Meehan AG; Williams-Herman DE; Kaufman KD; Amatruda JM; Steinberg H
Int J Clin Pract; 2011 Feb; 65(2):154-64. PubMed ID: 21235696
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
25. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Karasik A; Aschner P; Katzeff H; Davies MJ; Stein PP
Curr Med Res Opin; 2008 Feb; 24(2):489-96. PubMed ID: 18182122
[TBL] [Abstract][Full Text] [Related]
26. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
27. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
28. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
[TBL] [Abstract][Full Text] [Related]
29. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
[TBL] [Abstract][Full Text] [Related]
30. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
31. Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.
Imai C; Harazaki T; Inoue S; Mochizuki K; Goda T
J Nutr Sci Vitaminol (Tokyo); 2015; 61(4):313-21. PubMed ID: 26440638
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
33. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
[TBL] [Abstract][Full Text] [Related]
34. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
35. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
[TBL] [Abstract][Full Text] [Related]
36. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
37. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
[TBL] [Abstract][Full Text] [Related]
38. Effects of sitagliptin beyond glycemic control: focus on quality of life.
Sakamoto Y; Oyama J; Ikeda H; Kuroki S; Gondo S; Iwamoto T; Uchida Y; Kodama K; Hiwatashi A; Shimomura M; Taguchi I; Inoue T; Node K;
Cardiovasc Diabetol; 2013 Feb; 12():35. PubMed ID: 23432786
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
40. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]